Abstract:Importance: Meningiomas are the most common primary brain tumor and a heterogeneous disease with a need to study response to surgery and adjuvant RT in the context of contemporary molecular classifications. Objective: The gold standard for treatment of symptomatic meningiomas has been surgical resection including complete removal of tumor and its surrounding dural margin, although the necessity of different degrees of marginal resection is controversial. Adjuvant radiotherapy (RT) is generally reserved for aggressive or subtotally resected (STR) meningiomas. However, uncertainty exists regarding optimal case selection for RT and response to treatment is variable. We aimed to examine the effects of treatment (surgery/RT), molecular, and clinical factors on meningiomas in the context of molecular classifications. Design, Setting, and Participants: In this retrospective analysis, a 20-year cohort of 2490 patients with meningiomas were assembled across 10 institutions. Molecular data (DNA methylation, RNA sequencing) was generated for 1645 cases. Propensity score matching (PSM) was performed for key baseline covariates including WHO grade and molecular classifications, mimicking a randomized, molecular pathology informed clinical trial. Main Outcome and Measures: Progression-free survival (PFS), and overall survival (OS) were assessed based on extent of resection (EOR), Simpson grade, and receipt of adjuvant RT. Results: Gross total resection (GTR) was associated with improved PFS across all molecular groups. The PFS benefit of GTR was lessened in molecularly-defined proliferative meningiomas (HR 0.69, 95%CI 0.50-0.95), but OS benefit was enhanced (HR 0.52, 95%CI 0.30-0.93). Surgically treating the dural margin (Simpson grade 1/2) was associated with improved PFS compared to removal of tumor alone (Simpson grade 3) particularly for immunogenic (HR 0.16, 95%CI 0.03-0.82) and NF2-wildtype meningiomas (HR 0.24, 95%CI 0.11-0.53). Adjuvant RT was associated with improved PFS across all molecular classifications. Molecular groups could reliably predict response to RT, even when controlling for WHO grade and EOR with immunogenic and NF2-wildtype meningiomas benefitting most while proliferative meningiomas are largely RT-resistant (HR 0.96, 95%CI 0.67-1.37). Conclusion: This study is the first to investigate interactions between contemporary molecular classifications and response to both surgical resection and adjuvant RT in a large, multi-institutional cohort of molecularly defined, clinically annotated meningioma cases. Citation Format: Justin Z. Wang, Alexander P. Landry, Vikas Patil, Andrew Ajisebutu, Christopher D. Wilson, Aaron Cohen-Gadol, Ghazaleh Tabatabai, Silky Chotai, Jill Barnholtz-Sloan, Rebecca Yakubov, Mark Wilson, Ramneet Kaloti, Alexander Rebchuk, Damian A. Almiron Bonnin, Eric C. Holland, Stephen Yip, Felix Sahm, Kenneth Aldape, The International Consortium on Meningiomas, Farshad Nassiri, Gelareh Zadeh. Meningioma molecular classification predict response to surgical resection and adjuvant radiotherapy: An integrated clinicomolecular analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2346.

Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort

Management Approaches in WHO Grade III Meningioma: A National Oncology Trainees' Collaborative for Healthcare Research (NOTCH) UK Multi-Centre Retrospective Study

Current treatment options for meningioma

Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma

Multimodality Therapy of Patients with Refractory Meningiomas

1245 Malignant Meningioma Survival, Recurrence and Functional Outcomes in an International Multicenter Cohort

Management of Recurrent Meningiomas: State of the Art and Perspectives

Prognostic role of extent of resection and adjuvant radiotherapy in de novo anaplastic meningiomas

379 Meningioma Molecular Groups Predict Response to Adjuvant Radiotherapy Following Surgery

Surgical Management of High-Grade Meningiomas

Abstract 2346: Meningioma molecular classification predict response to surgical resection and adjuvant radiotherapy: An integrated clinicomolecular analysis

Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients

[Meningioma: management of the most common brain tumour]

Nonsurgical treatment options in the management of intracranial meningiomas

Radiation therapy for atypical and anaplastic meningiomas: an overview of current results and controversial issues

Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life

Medical treatment of recurrent meningiomas

A Case-based Guide for World Health Organization (WHO) Grade 2 Meningioma Radiosurgery and Radiation Therapy from The Radiosurgery Society

Surgery alone versus surgery plus adjuvant radiotherapy for WHO grade 2 meningioma: meta-analysis of reconstructed time-to-event data

Impact of extent of resection and adjuvant radiation therapy in the progression free survival in patients with spheno-orbital meningioma

Survival Impacts of Extent of Resection and Adjuvant Radiotherapy for the Modern Management of High-Grade Meningiomas